Compare SAMG & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | AARD |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.0M | 85.7M |
| IPO Year | 2012 | N/A |
| Metric | SAMG | AARD |
|---|---|---|
| Price | $13.30 | $3.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | 42.0K | ★ 242.6K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $8.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.79 | $3.35 |
| 52 Week High | $16.97 | $17.94 |
| Indicator | SAMG | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 31.63 |
| Support Level | $13.27 | $3.35 |
| Resistance Level | $16.83 | $4.39 |
| Average True Range (ATR) | 0.57 | 0.29 |
| MACD | 0.04 | 0.29 |
| Stochastic Oscillator | 31.06 | 65.38 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.